<DOC>
	<DOCNO>NCT01512745</DOCNO>
	<brief_summary>Apatinib tyrosin-inhibitor agent target vascular endothelial growth factor receptor ( VEGFR ) , 's anti-angiogenesis effect view preclinical test . The investigator ' phase I study show drug 's toxicity manageable maximum tolerable daily dose 850 mg . The purpose study determine whether apatinib improve progression free survival overall survival compare placebo patient metastatic gastric carcinoma fail two line chemotherapy .</brief_summary>
	<brief_title>Phase III Study Apatinib Tablets Treatment Advanced Metastatic Gastric Cancer</brief_title>
	<detailed_description />
	<mesh_term>Stomach Neoplasms</mesh_term>
	<criteria>≥ 18 ≤ 70 year age Histological confirm advanced metastatic adenocarcinoma stomach Have fail least 2 line chemotherapy Life expectancy least 12 week . Eastern Cooperative Oncology Group Performance Status 0 1 within 1 week randomization . At least one measurable lesion beyond stomach ( large 10 mm diameter spiral CT scan ) Duration last therapy 6 week nitroso mitomycin More 4 week operation radiotherapy More 4 week cytotoxic agent growth inhibitor Adequate hepatic , renal , heart , hematologic function ( HB ≥ 90g/L , platelet &gt; 80 ×10 E+9/L , neutrophil &gt; 1.5 × 10 E+9/L , serum creatinine ≤ 1× upper limit normal ( ULN ) , bilirubin &lt; 1.25× ULN , serum transaminase ≤ 2.5× ULN ) . Pregnant lactating woman History malignancy except cure basal cell carcinoma skin carcinoma insitu uterine cervix Hypertension unable control within normal level follow treatment antihypertension agent ( systolic blood pressure &gt; 140 mmHg , diastolic blood pressure &gt; 90 mmHg ) . Any factor influence usage oral administration ; Evidence Central Nerves System ( CNS ) metastasis Intercurrence one following : coronary artery disease , arrhythmia , heart failure proteinuria ≥ ( + ) International Normalize Ratio ( INR ) &gt; 1.5 activate partial thromboplastin time（APPT） &gt; 1.5 × ULN Abuse alcohol drug Certain possibility gastric intestine hemorrhage Less 4 week last clinical trial Prior VEGFR inhibitor treatment Disability serious uncontrolled intercurrence infection Objective evidence previous current pulmonary fibrosis history , interstitial pneumonia , Pneumoconiosis , radiation pneumonitis , drugrelated pneumonia , Pulmonary function damage seriously etc .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>April 2015</verification_date>
</DOC>